A Study of Intravesical Enfortumab Vedotin For Treatment of Patients With Non-muscle Invasive Bladder Cancer (NMIBC)
Public ClinicalTrials.gov record NCT05014139. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Study identification
- NCT ID
- NCT05014139
- Recruitment status
- Terminated
- Study type
- Interventional
- Phase
- Phase 1
- Lead sponsor
- Astellas Pharma Global Development, Inc.
- Industry
- Enrollment
- 37 participants
Conditions and interventions
Conditions
Interventions
- Enfortumab vedotin Drug
Drug
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Dec 6, 2021
- Primary completion
- Sep 21, 2025
- Completion
- Sep 21, 2025
- Last update posted
- Nov 19, 2025
2021 – 2025
United States locations
- U.S. sites
- 21
- U.S. states
- 14
- U.S. cities
- 20
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Banner MD Anderson Cancer Center | Gilbert | Arizona | 85234 | — |
| Mayo Clinic | Scottsdale | Arizona | 85259 | — |
| UCLA Department of Medicine - Hematology & Oncology | Los Angeles | California | 90095 | — |
| University of California, Irvine | Orange | California | 92868 | — |
| University of California at San Francisco | San Francisco | California | 94134 | — |
| Stanford Health Care | Stanford | California | 94305 | — |
| Northwestern University-Feinberg School of Medicine | Chicago | Illinois | 60611 | — |
| Rush University Medical Center | Chicago | Illinois | 60612 | — |
| Markey Cancer Center / University of Kentucky | Lexington | Kentucky | 40508 | — |
| Johns Hopkins Medical Center | Baltimore | Maryland | 21287 | — |
| Laura & Isaac Perlmutter Cancer Center at NYU Langone Health | New York | New York | 10016 | — |
| Duke University Medical Center | Durham | North Carolina | 27710 | — |
| James Cancer Hospital / Ohio State University | Columbus | Ohio | 43221 | — |
| Oregon Health and Science University | Portland | Oregon | 98682 | — |
| Sidney Kimmel Cancer Center | Philadelphia | Pennsylvania | 19107 | — |
| Carolina Urologic Research Center | Myrtle Beach | South Carolina | 29572 | — |
| Erlanger Oncology and Hematology | Chattanooga | Tennessee | 37403 | — |
| University of Texas Southwestern Medical Center | Dallas | Texas | 75390 | — |
| MD Anderson | Houston | Texas | 77030 | — |
| Urology San Antonio | San Antonio | Texas | 78229 | — |
| Fred Hutchinson Cancer Center / Seattle Cancer Care Alliance / University of Washington | Seattle | Washington | 98195 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 11 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT05014139, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Nov 19, 2025 · Synced May 12, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT05014139 live on ClinicalTrials.gov.